Shire offers support to individuals with Multifocal Motor Neuropathy (MMN) by providing educational resources, practical information, and important connections for you and your family.

Useful tools and clear information to help you manage your life with MMN.

Knowledge to help you have a meaningful conversation with your treatment team.

Connection with nurses with IVIG treatment experience to give you the knowledge and support to actively help with your healthcare experience. Nurse advocates do not provide medical advice.

To enroll in MyIgSource, call 1-855-250-5111 or enroll now

MyIgSource is open to all patients and caregivers regardless of treatment.

Nurse Advocates

Once enrolled in MyIgSource, you will be contacted by and have ongoing access to a nurse advocate who is experienced with IVIG infusions.

The key benefits are:

  • Individualized, live support
  • Ongoing support to help enhance your overall healthcare experience

MyIgSource is open to all patients regardless of treatment.

These helpful resources are available for you to download right now.

MyIgSource Summary: an overview of what to expect from MyIgSource for those who are currently on or starting IVIG treatment for MMN image

MyIgSource Summary

An overview of what to expect from MyIgSource for those who are currently on or starting IVIG treatment for MMN.

Key program benefits include:

  • Disease information
  • Individualized support
  • Educational resources
MMN Overview: An overview of MMN, including information about diagnosis, misdiagnosis, and treatment image

MMN Overview

An overview of MMN, including information about diagnosis, misdiagnosis, and treatment.

 

Electrodiagnostic Testing Summary: Provides an overview of electromyography and nerve conduction studies image

Electrodiagnostic Testing Summary

Provides an overview of electromyography and nerve conduction studies. These studies are one of several tools that your healthcare provider may use to identify the causes and severity of nerve damage.

To enroll in MyIgSource, call 1-855-250-5111

MyIgSource is open to all patients regardless of treatment.

References:

  1. Data on file. Baxter Healthcare Corporation. 2011.
  2. Meuth SG, Kleinschnitz C. Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol. 2010;63(4):193-204.

Speak with one of our experienced Nurse Advocates.

Call 1-855-250-5111 today!

GAMMAGARD LIQUID

was studied in the
largest clinical
trial in MMN
to date.1
Learn More

MMN affects men nearly

3x

more often than women.2

Learn More

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.

-----

Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.


© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Expand

Please expand for Indication and Detailed Important Safety Information.

Important Safety Information

What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.